ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma

2025/02/01 by Radka Obermannová, Trevor Leong · 1 voice
Medicine · #Esophageal Cancer Research and Treatment #Gastric Cancer Management and Outcomes #Lung Cancer Treatments and Mutations

paper · doi:10.1016/j.esmoop.2025.104134

openalex publication_date 2025/02/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01

Abstract

• This update provides recommendations for perioperative treatment of locally advanced oesophageal and OGJ adenocarcinoma. • Recent phase III data have demonstrated that perioperative ChT should be the preferred approach for most patients. • Updated recommendations are also provided for the use of immune checkpoint inhibitors in advanced squamous-cell carcinoma. • Algorithms for the management of locoregional oesophageal cancer and advanced squamous-cell carcinoma are provided. • Recommendations are based on available scientific data and the authors’ collective expert opinion.

Discussions

• 🔥hot off the press @ESMO_Open doi.org/10.1016/j.es... ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma an [bsky, 1 points, 0 comments]

Related

• Advances in Approaches to Managing Esophageal Adenocarcinoma
• Cancer of the esophagus and esophagogastric junction—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual
• The changing landscape of multimodal treatment for locally advanced oesophageal and junctional adenocarcinoma
• Tolerability, toxicity, and outcomes following surgical and non-surgical approaches to the management of patients with locally advanced oesophageal squamous cell carcinoma: multicentre retrospective cohort study
• Updates in staging and pathologic evaluation of esophageal carcinoma following neoadjuvant therapy